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Glucosidase inhibitorases prevent the trimming of oligosaccharides on certain nascent glycoproteins,
including the hepatitis B virus MHBs envelope glycoprotein. MHBs proteins with untrimmed oligosacchar-
ides do not interact with calnexin, increasing protein misfolding and subsequent degradation by
proteasomes. As peptides loaded onto newly synthesized MHC class I complexes are predominantly derived
from proteasomes, the possibility that glucosidase inhibition could increase presentation by MHC class I was
determined. Using either a model epitope, or a natural MHBs epitope, it was demonstrated that glucosidase
inhibitors enhanced presentation by MHC class I and promoted activation of antigen-speciﬁc CTLs,
suggesting a pharmacologic approach to immune modulation.
© 2008 Elsevier Inc. All rights reserved.Introduction
Major histocompatibility complex class I (MHC class I) molecules
present peptides generated by the proteasome for recognition by T
lymphocytes (Cresswell, 2001). Recognition of a peptide-MHC class I
complex by CD8+ cytolytic T cells (CTLs) results in T cell activation and
is critical to mounting a sustained cellular immune response.
Presentation of foreign intracellular antigenic peptides (such as from
viral proteins) by the MHC class I complex contributes to a successful
CTL-mediated immune response that eliminates infected cells. Con-
versely, it is thought that failure tomount an adequate Tcell response is
a key weakness that permits viruses such as hepatitis B virus (HBV) to
establish chronic infections (Chisari and Ferrari, 1995). It is thus
hypothesized that pharmacologic agents that selectively cause HBV
envelope proteins to misfold and become degraded would enhance
presentation of peptide epitopes by MHC class I. This hypothesis was
tested using a transfection assay that exploits an unusual dependence
of HBV on a host cell function. HBV speciﬁes three envelope proteins
called LHBs, MHBs and HBs (Bruss, 2004), all derived from a single
open reading frame with a common C terminal region. Folding and
secretion of MHBs is much more dependent upon the endoplasmic
reticulum (ER) chaperone calnexin than HBs (Werr and Prange, 1998),
and secretion of MHBs speciﬁcally requires glycan added at pre-S2
(Mehta et al., 1997). Calnexin recognizes monoglucosylated glycansNorton).
l rights reserved.present on nascent polypeptides as a consequence of normal
processing by ER glucosidases I and II (Helenius and Aebi, 2001).
Pharmacologic inhibition of ER glucosidases prevents trimming to
monoglucose, and thus prevents interaction with calnexin. The
calnexin-dependent biogenesis ofMHBs renders the protein extremely
sensitive to glucosidase inhibitors, a property shared by a number of
viral glycoproteins (Block and Jordan, 2002). We asked what impact
such inhibitors will have on the presentation of HBV epitopes to CTLs.
Results
The three HBV envelope proteins have differing amino termini, but
share a common C-terminus (Bruss, 2004). MHBs contain an
additional 55 amino acids N-terminal to HBs, referred to as the pre-
S2 region (Fig. 1A); LHBs contain pre-S2 and an additional ca. 110
amino acid N-terminal extension, termed pre-S1 region (not shown).
All three proteins can undergo N-linked glycosylation at amino acid
146 within the shared HBs domain. However, MHBs contain an
additional N-glycosylation site at amino acid 4 within pre-S2 (Fig. 1A).
Previously, it was established that genetic destabilization of MHBs
resulted in enhanced presentation by MHC class I to CTLs (Liu et al.,
2007a). We hypothesized that pharmacologic inhibition of glucosi-
dases might have a similar effect, as improper processing of glycan
structure is likely to destabilize MHBs. To determine whether
pharmacological inhibition of glucosidases could result in enhanced
presentation by class I to CTLs, a well-characterized T-cell epitope tag
presented by the mouseMHC class I Kb (SIINFEKL) that is derived from
Fig. 1. Expression of ovalbumin-tagged HBVmiddle glycoprotein MHBs in L-Kb cells. (A)
Diagram of the construct for expression of MHBs with the embedded Ova257–264 tag.
Complementary oligonucleotides were designed with cohesive ends to insert the
underlined sequences in frame with Pre-S2 at the EcoRI site (inverted triangle).
Diamonds indicate the position of sites of N-glycan addition, indicating that the N-
glycan site normally present at amino acid 4 is now at amino acid 23 (NST). The
asparagine at amino acid 4 is no longer within the context of an N-glycosylation sequon
(N-X-S/T) and thus will not be modiﬁed. (B) Immunoblot analysis of lysates prepared
from L-Kb cells transfected with a plasmid W/T-M-Ova and treated as indicated or left
untreated for 3 days post-transfection. Blot was probed with antibody directed against
the pre-S2 region; the three possible glycoforms of MHBs are indicated.
Fig. 2. Glucosidase inhibition increases epitope presentation by MHC class I. (A)
Relative levels of CTL activation following incubation with L-Kb target cells in the
presence of increasing amounts of drug. L-Kb cells were transfected with W/T-M-Ova
then treated as indicated for 3 days prior to incubation with B3.Z CD8+ hybridoma
cells, which speciﬁcally recognize the Ova epitope when presented in the context of
H-2Kb. Following incubation, cells were lysed and assayed for β-galactosidase activity.
Values shown indicate light output in counts per second (cps); each bar is the average
of duplicate determinations from a single experiment which varied by b10%. (B) Cell
treatments were as in A, with the addition of epoximicin (Epox) to some wells, but
levels shown are normalized to enzyme activity produced by incubation with
untreated transfected cells (set to unity). Error bars represent SEM of replicates (n=4).
b-gal, β-galactosidase.
13Rapid Communicationovalbuminwas introduced intoMHBs (W/T-M-Ova, (Liu et al., 2007a)).
Brieﬂy, oligodeoxynucleotides encoding amino acids 257–264 (SIIN-
FEKL, Ova257–264) along with ﬁve ﬂanking amino acids on each side
were inserted into the unique EcoRI site within the pre-S2 sequence of
MHBs expression construct pM(S–)X (Fig. 1A). Plasmid pM(S–)X
expresses MHBs but not HBs, due to mutation of the initiation codon
for the latter (Norton et al., 2005); the plasmid also contains the
HBxAg coding region, although expression of HBxAg has not been
established. The glycosylation site normally present at pre-S2 amino
acid 4 and required for secretion (Mehta et al., 1997) is now present
downstream of Ova257–264 in plasmid W/T-M-Ova, in a sequence
context that should still become glycosylated.
The mouse cell line L-Kb stably expresses the murine MHC class I
Kb protein (Golovina et al., 2005). Transfection of mouse L-Kb cells
with W/T-M-Ova resulted in production of MHBs, which migrated as
two species, representing protein either singly glycosylated at amino
acid 4 or doubly glycosylated at both sites (Fig. 1B). The second site is
glycosylated 50% of the time (Bruss, 2004), accounting for the doublet
appearance of the protein. Addition of the competitive glucosidase
inhibitor 6-O-butanoyl castanospermine (BuCas) at 1.0 mg/ml
resulted in a 2- to 3-fold reduction of the steady state level of
intracellular MHBs relative to untreated controls (Fig. 1B, lanes 1 and
2). Drug treatment resulted in reduced oligosaccharide trimming,
with both glycosylated species exhibiting reduced mobility relative to
untreated cells, indicating a failure to trim terminal glucoses, whereas
the mobility of unglycosylated p30 was unaffected. This indicates that
the Ova-tagged version of MHBs is sensitive to glucosidase inhibition
in L-Kb cells, as we have previously found for wild type MHBs in cells
of hepatocyte origin (Norton et al., 2005; Simsek et al., 2005).
Next, BuCas treated and untreated cultures were incubated with
B3.Z CTL hybridoma cells, which speciﬁcally recognize Ova257–264
presented in the context of H-2Kb. These cells contain a lacZ reporter
under the control of the NF-AT element from the interleukin-2
promoter (Karttunen and Shastri, 1991). Thus, occupancy of the T cell
receptor by the peptide/MHC complex triggers the expression of the
lacZ gene product, β-galactosidase, in the co-cultured B3.Z cells. In
the absence of BuCas treatment, baseline β-galactosidase levels were
slightly above the background levels observed B3.Z cells transfectedwith L-Kb cells expressing non-Ova tagged MHBs (Ova-) (Fig. 2A).
Since glucosidase inhibition resulted in a proteasome-dependent
degradation of MHBs (Simsek et al., 2005), and proteasomes are the
major source of the peptides that are loaded into MHC class I
complexes, we determined whether CTL recognition of L-Kb target
cells would increase following their treatment with BuCas. As shown
in Fig. 2A, treatment of MHBs-Ova transfected cells with BuCas
resulted in a dose-dependent increase in CTL activation relative to
untreated cells, indicating that drug treatment enhanced presentation
of Ova257–264 by MHC class I.
Wild type MHBs apparently undergoes little proteasomal degrada-
tion under normal conditions (Liu et al., 2007b; Simsek et al., 2005).
Although the nature of the resistance to degradation is not fully
understood, one possibility is that assembly of envelope glycoproteins
into larger lipoprotein particles shields them from the endoplasmic
reticulum-associated degradation (Block et al., 2006). However, alpha-
glucosidase inhibitors render the MHBs and LHBs glycoproteins much
more sensitive to proteasomal degradation (Simsek et al., 2005). Since
proteasomes are the predominant source ofMHC-I presented peptides
and, in cells in which glucosidase function is inhibited, proteasomal
degradation of HBV MHBs is increased (Simsek et al., 2005), we
reasoned that BuCas-induced increased antigen processing and
presentationwould be blocked by proteasome inhibitors. As expected,
inclusion of epoximicin (EPOX), a speciﬁc proteasome inhibitor that
14 Rapid Communicationdoes not inhibit non-proteasomal proteases (Schwarz et al., 2000),
blocked the BuCas-mediated increase in antigen-dependent CTL
activation (Fig. 2B).
It was of interest to establish whether the increased antigen
presentation obtained with glucosidase inhibition in this model
system would also be observed with naturally processed HBV
antigenic peptides. HepG2.2.15 cells were derived from the human
hepatoma line HepG2 and contain an integrated HBV genome that
produces all HBV nucleic acids and proteins and releases infectious
progeny (Sells et al., 1987). These cells are known to express HLA-A2
(Ito et al., 1993), so these cells were chosen as target cells for CTLs that
had been primed with previously described HBV-derived HLA-A2
peptides presented by human MHC class I HLA-A2.
PBMCs were isolated from a HLA-A2+ healthy human donor, and
incubated in the presence of a known HLA-A2-speciﬁc envelope
peptide derived from the common S domain, 183-FLLTRILTI (Chisari
and Ferrari, 1995), to induce antigen-speciﬁc cells. After three rounds
of stimulation of cells with peptide-pulsed autologous antigen
presenting cells, activated CTLs were incubated with drug treated or
untreated HepG2.2.15 target cells (incubation of effector and target
cells was performed overnight in the absence of drug). Co-cultures
were assayed for antigen-speciﬁc activated CTLs using the ELISpot
assay for IFN-gamma secretion as a function of CTL response, at a T
cell:target ratio of 20:1 (Fig. 3). Antigen presenting T2 cells lacking any
HBV proteins served as a negative control; pulsing these cells with
peptide resulted in an increase in T cell response, showing antigen
speciﬁcity (Fig. 3, upper right). HepG2.2.15 cells presented the 183-
FLLTRILTI epitope at a basal level, presumably processed from viral
envelope proteins. However, BuCas-treated HepG2.2.15 cells stimu-
lated twice as much IFN-gamma production as untreated cells,
suggesting increased presentation of the 183-FLLTRILTI epitope by
the drug treated target cells (Fig. 3, lower right). CTL activation was
completely blocked by inclusion of epoximicin, indicating proteasome
dependence.
In contrast to the effect of BuCas treatment on 183-FLLTRILTI
presentation, no effect was observed when CTLs were primed with
another HLA-A2-restricted HBV peptide 18-FLPSDFFPSV derived from
the viral core antigen (Chisari and Ferrari, 1995), that is not known to
be glycosylated (Fig. 3, lower left). Thus, glucosidase inhibition
resulted in enhanced presentation of a viral epitope due to speciﬁc
destabilization of one or more of the envelope glycoproteins.Fig. 3. Glucosidase inhibition increases envelope peptide-speciﬁc CTL response. In vitro gen
target ratio of 20:1 overnight and IFN-gamma productionwas measured using human IFN-ga
or HepG2.2.15 (HBV expressing cells) that were either left untreated or treated with the in
producing cells per 106 CD8+ T cells. Error bars represent SEM of experimental replicates (nDiscussion
These data demonstrate that pharmacologic inhibition of cellular
glucosidases results in enhanced proteasomal degradation of the viral
glycoprotein MHBs, with increased MHC class I-mediated presenta-
tion of an embedded T cell epitope tag. This is presumably due to
reduction of viral glycoprotein secretion as a consequence of
interfering with calnexin-mediated protein folding. Moreover, the
increased recognition of HBV-infected cells by antigen-primed CTLs
suggests that by rendering MHBs more susceptible to the proteasome,
the glucosidase inhibitor has thus increased the possibility that viral
antigens will be processed and be available for loading into MHC class
I. However, as the accumulation of intracellular MHBs (Fig. 1B) is more
modest than might be expected based on the CTL assay (Fig. 2), there
might be other factors promoting antigen presentation. The relation-
ship between protein degradation rate and presentation efﬁciency is
incompletely understood (Eisenlohr et al., 2007), with multiple steps
that must occur for glycoproteins that undergo endoplasmic reticu-
lum-associated degradation.
Although the nature of the resistance of HBVMHBs to proteasomal
degradation that we have reported previously is not clear (Liu et al.,
2007b; Simsek et al., 2005), the consequences are of potential
importance in the context of chronic viral infection. If viral
glycoproteins are unable to be degraded, peptides will not be available
for presentation by MHC class I, which may result in deﬁcient CTL
responses to virally infected cells. As summarized in a recent review,
there are likely to be several reasons for the inadequate CTL response
observed in chronic HBV infection, including deﬁciencies in antigen
presentation (Guidotti and Chisari, 2006). HBV and the related
woodchuck hepatitis virus have also been reported to reduce
expression of MHC class I (Chen et al., 2006; Wang and Michalak,
2006), suggesting a more active role in immune evasion. In the case of
the woodchuck virus, WHV, the pre-S2 region of the MHBs protein
(see Fig. 1) has been implicated in a modest but signiﬁcant reduction
in surface MHC class I levels on hepatocytes that had been transfected
with WHV MHBs (Wang and Michalak, 2006), although a similar role
for pre-S2 as encoded by the human virus is not known. Thus,
presentation of HBV antigens may be affected by several factors.
Imino sugars that inhibit cellular glucosidases, such as BuCas, have
been approved for use in lysosomal glycosphingolipidoses (Butters et
al., 2005). BuCas has been advanced to Phase II clinical trials againsterated peptide speciﬁc CTLs were co-cultured with various target cells at an effector to
mma ELISpot reagents. Targets were unpulsed or peptide (Pep) pulsed T2 cells or HepG2
dicated drugs (BuCas or Epoximicin). Results are presented as number of IFN-gamma
=3).
15Rapid Communicationhepatitis C virus, with some promise when used in combination with
other (Durantel et al., 2007). The immunomodulatory activity of
glucosidase inhibitors was previously unrecognized, and is somewhat
unexpected, as it has been reported that glucosidase inhibition can
destabilize unassembled MHC class I molecules (Moore and Spiro,
1993). The results presented in the present report suggest a possible
new therapeutic role for using this class of pharmacologic agents
against other chronic viral infections in which a CD8+ CTL response is
deﬁcient, and the viral envelope glycoprotein might be sensitive to
glucosidase inhibition, such as HBV.
Materials and methods
The mouse cell lines L-Kb and B3.Z CTL cells were a kind gift of by
Dr. L. Eisenlohr, Thomas Jefferson University, Philadelphia, PA. T2 cells,
obtained from American Type Culture Collection (ATCC; Manassas,
VA), are HLA-A2 expressing human T cell–B cell somatic hybrid cells
that are defective in transporting of MHC class I presented antigenic
peptides across ER membrane. Consequently, T2 cells express ‘empty’
(peptide receptive) HLA-A2 molecules on the cell surface. Human
HepG2 (ATCC) cells were derived from a well-differentiated hepato-
cellular carcinoma. HepG2.2.15 cells were derived fromHepG2 cells by
stable transfection of HBV genome and were a gift of Dr. G Acs. 6-O-
butanoylcastanospermine (BuCas, also called Celgosivir) was a gift of
Migenix, Inc., Vancouver, BC. The construction of plasmidW/T-M-Ova,
transfection of cells and immunoblotting with an antibody that
recognizes the pre-S2 region (Research Diagnostics, Inc., Somerset, NJ)
was as described previously (Liu et al., 2007a).
Target L-Kb cells were treated with BuCas for a total of 3 days. B3.Z
CTL cells were added on day two and the co-cultures incubated
overnight. No cell toxicity was observed at any dose tested (data not
shown). In cases when epoximicinwas included, it was added only for
the ﬁnal overnight incubation. The lacZ gene product, β-galactosidase,
was measured in cell lysates using a chemiluminescence-based assay
(Galactolight Plus, Applied Biosystems, Bedford, MA).
In vitro generation of peptide speciﬁc human CTLs was achieved
according to standard methods. Brieﬂy, heparinized blood from a
healthy HLA-A2+ human donor (Research Blood Components,
Brighton, MA) was used to generate CTL. Peripheral blood mono-
nuclear cells were puriﬁed using lymphocyte separation medium
(Mediatech, Manassas, VA) using differential centrifugation according
to standard methods. 20×106 cells were plated per well in 2 ml RPMI
1640medium supplementedwith 10% fetal bovine serum, L-glutamine
(300 μg/ml), non-essential amino acids, sodium pyruvate, penicillin
and streptomycin (complete medium) in 6-well tissue culture plates
(BD, Franklin Lakes, NJ) overnight. Non-adherent cells were removed
and saved. Plastic adherent cells were pulsed with 50 μg/ml synthetic
peptide and 1.5 μg/ml human β2-microglobulin (Sigma-Aldrich, St.
Louis, MO) in complete medium for 2 h. Medium was removed and
non-adherent cells were added in 5 ml complete medium supple-
mented with IL-7 at 5 ng/ml, Keyhole Limpet Hemocyanin (KLH;
Sigma) at 5 μg/ml, Granulocyte Monocyte Colony Stimulating Factor
(GM-CSF) at 25 ng/ml and IL-4 at 50 ng/ml (all cytokines and growth
factors were from Peprotech, Rocky Hill, NJ). Plates were incubated at
37 °C in a humidiﬁed incubatorwith 5% CO2 for 12 days. 2.5mlmedium
was removed from each well and replaced with fresh complete
medium supplemented with 10 U/ml IL-2 for 2 days. T cells were
restimulated with CD4/CD8 T cell depleted autologous monocytes
pulsed with synthetic peptide at 10 μg/ml and 1.5 μg/ml human β2-
microglobulin in complete medium containing 5 ng/ml IL-7 and 5 μg/
ml KLH for 5 days. IL-2 treatment and in vitro restimulation were
repeated thrice at weekly intervals prior to use of in vitro expanded T
cells in ELISpot assays. In vitro expanded T cells were used as effectorsin ELISpot assays to assess antigen stimulated interferon-γ release
using human interferon-γ assay kit (BD-Pharmingen, San Jose, CA)
according to the manufacturer's instructions.
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